• Stryker for vascular surgeons.
• A specialized Medtronic for peripheral vascular devices.

• Angioscope: A fiberoptic catheter used for viewing the lumen of a blood vessel.
• Embolectomy Catheters: Used to remove blood clots from arteries or veins.
• Occlusion Catheters: Temporarily occlude blood flow.
• Perfusion Catheters: Perfuse blood and other fluids into the vasculature.
• Thrombectomy Catheters: Feature a silicone balloon for removing thrombi in the venous system.
• Carotid Shunts: Temporarily shunt blood to the brain during carotid endarterectomy surgery.
• Radiopaque Tape: A medical-grade tape applied to the skin for cross-referencing between inside and outside of a patient's body.
• Valvulotomes: Cut or disrupt valves in the saphenous vein to function as an artery.
• Vascular Grafts: Bypass or replace diseased arteries.
• Vascular and Cardiac Patches: Used for closure of vessels after surgical intervention.
• Closure Systems: Attach vessels to one another with titanium clips instead of sutures.

LeMaitre Vascular (LMAT) sells specialized medical devices and implants primarily to other companies and institutions, not directly to individuals.

Based on the provided company description, specific names of major customer companies are not identified. However, the company states it "markets its products through a direct sales force and distributors."

Therefore, LeMaitre Vascular's major customers are generally:

• Hospitals and Surgical Centers: These medical institutions directly purchase and utilize the company's devices and implants for surgical procedures related to peripheral vascular disease.
• Medical Device Distributors: These companies purchase LeMaitre Vascular's products and then sell them to various healthcare providers and institutions.

null

George W. LeMaitre, Chairman & CEO

George W. LeMaitre has served as Chief Executive Officer and a member of the Board of Directors of LeMaitre Vascular since 1992, and as Chairman since 2004. His father, Dr. George D. LeMaitre, founded the company (originally named Vascutech) in 1983, and George W. LeMaitre joined in 1992, helping to grow it from a family-owned business into a publicly held global provider of medical devices. Prior to joining LeMaitre, he worked as an investment banking analyst at Lehman Brothers, an associate at the leveraged buyout firm McCown De Leeuw, and a credit analyst for Connecticut National Bank.

Dorian LeBlanc, CFO

Dorian LeBlanc joined LeMaitre Vascular as Chief Financial Officer in March 2025.

David B. Roberts, President, Board Director

David B. Roberts has served as President of LeMaitre Vascular since 2007 and as a member of its Board of Directors since 2001. He joined the company in 1997 as Vice President of Business Development and was promoted to Chief Financial Officer in 2000, a position he held until 2007. Before LeMaitre Vascular, Mr. Roberts worked at BUCA, Inc. from 1994 to 1997 and as an Associate at HarbourVest Partners, a private equity firm, from 1992 to 1994.

Trent G. Kamke, SVP, Operations

Trent G. Kamke has served as Senior Vice President, Operations since 2005. He joined LeMaitre Vascular in 1997 as Quality Assurance Manager and served as Vice President, Operations from 1999 to 2005. Prior to joining the company, Mr. Kamke was employed by Haemonetics Corporation.

Jonathan W. Ngau, SVP, Information Technology

Jonathan W. Ngau has served as Senior Vice President, Information Technology since April 2024. Since joining LeMaitre Vascular in 1996, Mr. Ngau has been responsible for implementing and managing all information technology, application development, infrastructure operations, business intelligence, compliance, and cybersecurity for the company's facilities. He previously served as Director of Information Technology in 2000 and Vice President, Information Technology in 2003.

The key risks to LeMaitre Vascular's business operations include navigating a dynamic regulatory landscape, intense competition coupled with technological shifts in treatment modalities, and pressures related to healthcare spending, pricing, and reimbursement.

1. Dynamic Regulatory Landscape and Product Approvals: As a medical device company, LeMaitre Vascular operates within a highly regulated industry. The company faces ongoing risks associated with obtaining and maintaining regulatory approvals for its products across various global markets. A dynamic regulatory landscape presents continuous challenges, and regulatory hurdles can significantly impede international expansion and impact profit margins.
2. Competition and Technological Shifts: LeMaitre Vascular operates in a competitive market, facing challenges from larger medical technology companies with broader product portfolios and more extensive distribution networks. There is also a risk of market share erosion due to the industry's shift towards minimally invasive endovascular procedures, which could render some of LeMaitre Vascular's open vascular surgery products less competitive or potentially obsolete over time. The company's focus on a relatively narrow set of vascular products makes it potentially more exposed if major competitors aggressively enter overlapping procedure areas.
3. Healthcare Spending, Pricing, and Reimbursement Pressures: The company is susceptible to external pressures on healthcare spending, including lower reimbursement rates and slower adoption rates internationally, which could negatively impact future earnings. Insurers' tactics to manage medical loss ratios can also lead to downward pressure on reimbursement rates for healthcare providers, ultimately affecting demand and pricing for LeMaitre Vascular's devices.

null

LeMaitre Vascular (LMAT) operates within several addressable markets for its specialized medical devices and implants. The company estimates that the annual worldwide market for peripheral vascular devices exceeds $9 billion, with approximately $1 billion of that market addressable by LeMaitre Vascular's specific products.

Here are the addressable market sizes for some of LeMaitre Vascular's main products:

• Artegraft: The total addressable market for Artegraft in Europe is estimated to be approximately $30 million.
• Vascular Grafts: The global vascular grafts market was estimated at USD 1.7 billion in 2023 and is projected to reach USD 2.8 billion by 2030. Another estimate places the global market at USD 3.6 billion in 2024, with projections to reach USD 7.3 billion by 2034.
• Embolectomy Catheters: The global embolectomy balloon catheter market size was valued at approximately USD 1.2 billion in 2023 and is anticipated to reach USD 2.4 billion by 2032.
• Carotid Shunts: The global carotid shunt market was valued at $119 million in 2023 and is expected to increase to $147 million by 2030.
• Valvulotomes (Cardiac Valvulotome): The global cardiac valvulotome market size was estimated at USD 115.87 million in 2024 and is predicted to reach approximately USD 184.51 million by 2034.
• Vascular and Cardiac Patches (Cardiovascular and Soft Tissue Repair Patches): The global cardiovascular and soft tissue repair patches market size was estimated at USD 3.8 billion in 2021 and is projected to reach USD 7.8 billion by 2030. More recent estimates value the market at USD 4.84 billion in 2024, with projections to grow to USD 10 billion by 2033.

LeMaitre Vascular, Inc. (LMAT) anticipates several key drivers of future revenue growth over the next two to three years: * Strategic Price Increases: The company has demonstrated consistent pricing power, with organic revenue growth in Q4 2025 driven significantly by a 9% price increase, alongside unit gains. Management has also guided for an approximate 8% blended U.S. price increase for 2026, indicating this will continue to be a factor in revenue growth. * International Expansion and Market Penetration: LeMaitre Vascular is actively pursuing growth in international markets, as evidenced by strong regional performance in EMEA (29% growth) and APAC (20% growth) in full-year 2025. The international rollout of its Artegraft product is a significant driver, with 2025 sales doubling initial guidance and a projected $10 million in international Artegraft sales for 2026. The company is also expanding its direct sales model into new countries, such as Poland and other European markets, and is pursuing approvals for Artegraft in various countries including Canada, Australia, Japan, Korea, Thailand, and Singapore. * Growth from Key Product Lines, particularly Artegraft: Strong demand for existing key product lines, such as grafts (up 27%), valvulotomes (up 20%), and shunts (up 18%) in Q4 2025, continues to contribute to revenue. Artegraft, a biologic graft, is a major focus, being the largest U.S. product in 2024 and expected to drive substantial growth internationally. * Expansion of Direct Sales Force: LeMaitre Vascular is investing in its sales team, having added 12 new sales professionals in Q1 2024 and planning for a larger sales force in 2026. This expansion of its commercial footprint is expected to enhance market penetration and drive increased sales.

Share Repurchases

• On February 19, 2026, LeMaitre Vascular's Board of Directors authorized a new share repurchase program for up to $100.0 million of its common stock. This program is effective until February 18, 2027, unless extended.
• Previously, on February 18, 2025, the Board authorized a share repurchase program of up to $75.0 million of common stock, which was set to conclude on February 17, 2026.

Share Issuance

• LeMaitre Vascular's shares outstanding increased by 0.66% in the year prior to March 2026.
• From December 31, 2021, to September 30, 2025, the company's shares outstanding increased from 0.021 billion to 0.024 billion.
• Insider buying activity included the Chairman and CEO, George W. LeMaitre, acquiring 47,440 shares in the 90 days leading up to February 15, 2026.

Outbound Investments

• LeMaitre Vascular acquired the business and assets of Artegraft, Inc. for $90.0 million. This included $72.5 million in cash paid at closing (with $7.5 million in escrow to be released by December 31, 2021) and potential earnout payments of $17.5 million based on future sales. The acquisition expanded LeMaitre's biologic and dialysis access product offerings.

Capital Expenditures

• In the 12 months prior to March 2026, LeMaitre Vascular's capital expenditures amounted to $6.78 million.